Skip to main content
Jill Smith, MD, Gastroenterology, Washington, DC

JillPSmithMD

Gastroenterology • Washington, DC

Hepatology & Liver Transplantation, Pancreas Disease

Professor, Medicine, Georgetown University College of Medicine

Join to view full profile

Dr. Smith is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Smith's full profile

Already have an account?

  • Office

    3800 Reservoir Rd NW
    Pasquerilla Healthcare Center, 6th Floor
    Washington, DC 20007
    Phone+1 202-444-8168
    Fax+1 877-303-1460

Summary

  • Dr. Jill Smith is a Clinician Scientist that is involved in treating patients, carrying out translational research lab, and she teaches and mentors graduate, medical students, residents and fellows. She is a board certified internist /gastroenterologist in Washington, DC and Full Professor at Georgetown University. She also sees veterans at the Washington DC Veterans Affairs Medical Center in the Hepatology clinics. She received her medical degree from University of Florida College of Medicine and did her residency / fellowship at University of Missouri. She specializes in hepatology & liver transplantation and pancreas diseases. She has more than 100 publications and over 500 citings.

Education & Training

  • University of Missouri-Columbia
    University of Missouri-ColumbiaFellowship, Gastroenterology, 1985 - 1987
  • University of Missouri-Columbia
    University of Missouri-ColumbiaResidency, Internal Medicine, 1981 - 1983
  • University of Florida College of Medicine
    University of Florida College of MedicineClass of 1980

Certifications & Licensure

  • DC State Medical License
    DC State Medical License 2014 - 2026
  • PA State Medical License
    PA State Medical License 1987 - 2024
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

  • Innovator of the Year award Georgetown University, 2024
  • Harrington Discovery Scholar Innovator Award Cleveland Clinics- Harrington, 2021
  • Biochemistry Graduate School Mentoring Award Georgetown University, 2019
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Cholecystokinin and pancreatic cancer: the chicken or the egg?  
    Smith JP, Solomon TE, Gastrointest Liver Physiol 2014;306:G91-G101
  • Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice  
    Smith JP, Cooper TK, McGovern CO, et al, Pancreas 2014;43:1050-9

Press Mentions

  • Cancer Advances, Inc. Announces Publication, "Gastrin Vaccine Alone and in Combination with an Immune Checkpoint Antibody Inhibits Growth and Metastases of Gastric Cancer" in Frontiers in Oncology
    Cancer Advances, Inc. Announces Publication, "Gastrin Vaccine Alone and in Combination with an Immune Checkpoint Antibody Inhibits Growth and Metastases of Gastric Cancer" in Frontiers in OncologyDecember 6th, 2021
  • Cancer Advances, Inc. Announces Publication, “Vaccination with Polyclonal Antibody Stimulator (PAS) Prevents Pancreatic Carcinogenesis in the KRAS Mouse Model" in Cancer Prevention Research
    Cancer Advances, Inc. Announces Publication, “Vaccination with Polyclonal Antibody Stimulator (PAS) Prevents Pancreatic Carcinogenesis in the KRAS Mouse Model" in Cancer Prevention ResearchAugust 24th, 2021
  • Naltrexone at Low Doses Upregulates a Unique Gene Expression Not Seen with Normal Doses: Implications for Its Use in Cancer Therapy
    Naltrexone at Low Doses Upregulates a Unique Gene Expression Not Seen with Normal Doses: Implications for Its Use in Cancer TherapySeptember 27th, 2016

Grant Support

  • The CCK-B receptor signaling pathway as a driver of pancreatic cellular plasticity and carcinogenesisNIH /NCI2023–2028
  • Activation of Cholecystokinin-B Receptor-Positive Stem Cells Induces Hepatic CarcinogenesisDOD2021–2024
  • Targeted nanoparticle for early diagnosis & treatment of pancreatic cancerAACR2021–2023
  • Proglumide and the Pancreatic Tumor MicroenvironmentPancreatic Action Network2020–2023
  • Phase 1 study to test safety and dose of proglumide as an anti-fibrotic agentNCI2019–2021
  • High fat diet stimulates pancreatic cancer through the actions of CholecystokininNCI2015–2018
  • The Cholecystokinin-C (Cck-C) Receptor For Early Detection Of Pancreatic CancerNational Cancer Institute2007–2010
  • The Efficacy Of Low Dose Naltrexone Therapy In Children With Crohn'SNational Center For Research Resources2009
  • Clinical Trial: OGF &Gemcitabine: Novel Treatment For Pancreatic CancerNational Center For Research Resources2009
  • OGF &Gemcitabine: A Novel Treatment For Pancreatic Cancer: Phase I StudyNational Cancer Institute2008–2009
  • The Effects Of Naltrexone On Active Crohn'S DiseaseNational Center For Research Resources2007–2009
  • Effects Of Silencing RNAS For Gastrin And CCK On Human Pancreatic CancerNational Cancer Institute2007–2008
  • Treatment Of Advanced Pancreatic Cancer With Opioid Growth Factor Phase IINational Center For Research Resources2005–2008
  • Effects Of Naltrexone On Active Crohn'S DiseaseNational Institute Of Diabetes And Digestive And Kidney Diseases2006–2007
  • Efficacy Of Low Dose Naltrexone Therapy In Crohn'S DiseaseNational Center For Research Resources2005–2006
  • Treatment Of Advanced Pancreatic Cancer With Growth Fac*Food And Drug Administration2005
  • Low Dose Naltrexone Therapy In Crohn'S DiseaseNational Center For Research Resources2004
  • Gastrointestinal Peptides And Pancreatic CancerNational Cancer Institute2001–2004
  • Peptides And Pancreatic CancerNational Cancer Institute2002–2003
  • Treatment Of Hepatitis C With Amantadine: Dose Escalation StudyNational Center For Research Resources2000–2002
  • Treating Advanced Pancreatic Cancer With Opioid Growth Factor, Phase INational Center For Research Resources2000–2002
  • Treatment Of Chronic Hepatitis C With Amantadine HydrochlorideNational Center For Research Resources1997–2002
  • Peptides And Pancreatic CanerNational Cancer Institute1999–2001
  • Opioid Growth Factor And Pancreatic Cancer--Phase 1National Cancer Institute1999–2000
  • Treatment Of Chronic Hepatitis C With Amantadine Hc1National Institute Of Allergy And Infectious Diseases1998–1999
  • Cholecystokinin Of Pancreatic CancerNational Cancer Institute1995–1997
  • Effects Of Cholecystokinin On Human Pancreatic CancerNational Cancer Institute1989–1993

Dr. Jill Smith, Dr. Jill Smith, MD, Dr. J Smith, Dr. Jill P Smith